- Market Capitalization, $K 3,955,624
- Shares Outstanding, K 65,523
- Annual Sales, $ 605,720 K
- Annual Income, $ -348,900 K
- 60-Month Beta 0.55
- Price/Sales 6.50
- Price/Cash Flow N/A
- Price/Book 1.21
|Period||Period Low||Period High||Performance|
| || |
-11.68 (-16.21%)since 06/25/21
| || |
-20.74 (-25.57%)since 04/27/21
| || |
-135.44 (-69.17%)since 07/27/20
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
- Biologic effect of salt inducible kinase (SIK) mechanism in first patient studies supports further progression of Toledo portfolio
- Generally safe and well tolerated
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn's and Colitis Organisation (ECCO) virtual congress
Mechelen, Belgium; 22 June 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year.
Mechelen, Belgium; 7 June 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
Mechelen, Belgium; 4 June 2021; 07.01 CET; - Galapagos NV (Euronext & Nasdaq: GLPG) today announced that primary and secondary endpoint results from the phase 3 SELECTION induction and maintenance study...
Mechelen, Belgium, 27 May 2021, 22:01 CET, - Galapagos NV (Euronext & Nasdaq: GLPG) today announced that 15 abstracts, including scientific updates, and data providing further understanding on the profile...
The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...
|Galapagos NV ADR|
|GS Innovate Equity ETF|
|FTSE RAFI Dev Markets Ex-U.S. Small-Mid Invesco|
|S&P Intl Developed Quality Invesco ETF|
|Europe ETF FTSE Vanguard|
|Purebetasm FTSE Developed Ex-North America ETF|
|3rd Resistance Point||62.24|
|2nd Resistance Point||61.40|
|1st Resistance Point||60.88|
|1st Support Level||59.52|
|2nd Support Level||58.68|
|3rd Support Level||58.16|